Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 23, 2017, Neuralstem, Inc. (the Company) reported its
financial results and year-end business results for the year
ended December 31, 2016 and provided an update on clinical
programs and business highlights. The press release is attached
as Exhibit99.01 and is incorporated herein by reference.
The information furnished under Items 2.02, including the
accompanying Exhibit 99.01 shall not be deemed to be filed for
the purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act), or otherwise subject to the liability of such
section, nor shall such information be deemed to be incorporated
by reference in any subsequent filing by the Company under the
Securities Act of 1933 or the Exchange Act, regardless of the
general incorporation language of such filing, except as
specifically stated in such filing.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description |
| 99.01 | Press Release Dated March 23, 2017 |
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. (NASDAQ:CUR) Recent Trading Information
Neuralstem, Inc. (NASDAQ:CUR) closed its last trading session up +0.18 at 5.41 with 133,976 shares trading hands.
